ORIC Pharmaceuticals, Inc. Appoints Lori Friedman as Chief Scientific Officer
July 09, 2019 at 07:52 am EDT
Share
ORIC Pharmaceuticals, Inc. announced that Lori Friedman, has been named Chief Scientific Officer. Dr. Friedman will serve on the executive leadership team and lead the company's research and preclinical development efforts. Dr. Friedman brings to the company over 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics, drug discovery, pharmacology and biomarkers.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
ORIC PHARMACEUTICALS, INC. 
